{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:45:34Z","timestamp":1792014334389,"version":"4.4.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-025-13757-8","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:44:53Z","timestamp":1764953093000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Projecting lifetime HIV-related healthcare costs for youth with HIV in the United States"],"prefix":"10.1186","volume":"26","author":[{"given":"Michelle L.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata E.","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Espada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunjal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare F.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Rutstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison L.","family":"Agwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth A.","family":"Freedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Trent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Giardina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily P.","family":"Hyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Ciaranello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Neilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"13757_CR1","unstructured":"Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas. 2019. 32. https:\/\/stacks.cdc.gov\/view\/cdc\/149036. Accessed 10 September 2024."},{"issue":"4","key":"13757_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/QAI.0000000000002280","volume":"83","author":"AM Neilan","year":"2020","unstructured":"Neilan AM, Lu F, Gebo KA, et al. Higher acuity resource utilization with older age and poorer HIV control in adolescents and young adults in the HIV research network. J Acquir Immune Defic Syndr. 2020;83(4):424\u201333. https:\/\/doi.org\/10.1097\/QAI.0000000000002280.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"13757_CR3","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/INF.0000000000000126","volume":"33","author":"SA Berry","year":"2014","unstructured":"Berry SA, Gebo KA, Rutstein RM, et al. Trends in hospitalizations among children and young adults with perinatally acquired HIV. Pediatr Infect Dis J. 2014;33(5):488\u201394. https:\/\/doi.org\/10.1097\/INF.0000000000000126.","journal-title":"Pediatr Infect Dis J"},{"key":"13757_CR4","volume-title":"Access and utilization of selected preventive health services among adolescents aged 10\u201317","author":"LI Black","year":"2016","unstructured":"Black LI. Access and utilization of selected preventive health services among adolescents aged 10\u201317. No 246. Hyattsville Md: NCHS Data Brief: National Center for Health Statistics; 2016."},{"issue":"5","key":"13757_CR5","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1001\/jama.2011.79","volume":"305","author":"AL Agwu","year":"2011","unstructured":"Agwu AL, Jang SS, Korthuis PT, Araneta MRG, Gebo KA. Pregnancy incidence and outcomes in vertically and behaviorally HIV-infected youth. JAMA. 2011;305(5):468. https:\/\/doi.org\/10.1001\/jama.2011.79.","journal-title":"Jama"},{"issue":"12","key":"13757_CR6","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1097\/MLR.0b013e3181f81c4a","volume":"48","author":"JA Fleishman","year":"2010","unstructured":"Fleishman JA, Yehia BR, Moore RD, Gebo KA. The economic burden of late entry into medical care for patients with HIv infection. Med Care. 2010;48(12):1071\u201379. https:\/\/doi.org\/10.1097\/MLR.0b013e3181f81c4a.","journal-title":"Med Care"},{"issue":"4","key":"13757_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/MLR.0000000000000308","volume":"53","author":"BR Schackman","year":"2015","unstructured":"Schackman BR, Fleishman JA, Su AE, et al. The lifetime medical cost savings from preventing HIV in the United States. Med Care. 2015;53(4):293\u2013301. https:\/\/doi.org\/10.1097\/MLR.0000000000000308.","journal-title":"Med Care"},{"issue":"2","key":"13757_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/QAI.0b013e3182973966","volume":"64","author":"PG Farnham","year":"2013","unstructured":"Farnham PG, Gopalappa C, Sansom SL, et al. Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care. J Acquir Immune Defic Syndr. 2013;64(2):183\u201389. https:\/\/doi.org\/10.1097\/QAI.0b013e3182973966.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"13757_CR9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/OLQ.0000000000001366","volume":"48","author":"A Bingham","year":"2021","unstructured":"Bingham A, Shrestha RK, Khurana N, Jacobson EU, Farnham PG. Estimated lifetime HIV-related medical costs in the United States. Sex Transm Dis. 2021;48(4):299\u2013304. https:\/\/doi.org\/10.1097\/OLQ.0000000000001366.","journal-title":"Sex Transm Dis"},{"issue":"4","key":"13757_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/OLQ.0000000000001380","volume":"48","author":"HW Chesson","year":"2021","unstructured":"Chesson HW, Spicknall IH, Bingham A, et al. The estimated direct lifetime medical costs of sexually transmitted infections acquired in the United States in 2018. Sex Transm Dis. 2021;48(4):215\u201321. https:\/\/doi.org\/10.1097\/OLQ.0000000000001380.","journal-title":"Sex Transm Dis"},{"key":"13757_CR11","unstructured":"ATN HIV. The adolescent medicine trials network for HIV interventions. https:\/\/www.atnconnect.org\/. Accessed 10 September 2024."},{"issue":"9","key":"13757_CR12","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1007\/s10461-021-03169-0","volume":"25","author":"AM Neilan","year":"2021","unstructured":"Neilan AM, Bangs AC, Hudgens M, et al. Modeling adherence interventions among youth with HIV in the United States: clinical and economic projections. AIDS Behav. 2021;25(9):2973\u201384. https:\/\/doi.org\/10.1007\/s10461-021-03169-0.","journal-title":"AIDS Behav"},{"issue":"5","key":"13757_CR13","doi-asserted-by":"publisher","first-page":"e240816","DOI":"10.1001\/jamahealthforum.2024.0816","volume":"5","author":"AM Neilan","year":"2024","unstructured":"Neilan AM, Ufio OL, Brenner IR, et al. Projected life expectancy for adolescents with HIV in the us. JAMA Health Forum. 2024;5(5):e240816. https:\/\/doi.org\/10.1001\/jamahealthforum.2024.0816.","journal-title":"JAMA Health Forum"},{"key":"13757_CR14","unstructured":"Centers for Disease Control and Prevention. Diagnoses of hiv infection in the United States and dependent areas, 2021. HIV Surveillance Report. 2021;34. https:\/\/stacks.cdc.gov\/view\/cdc\/149071. Accessed 10 September 2024."},{"key":"13757_CR15","unstructured":"HIV Surveillance Supplemental Report. Monitoring selected national HIVPrevention and care objectivesby using surveillance DataUnited states and 6 dependent areas. 2019;26(2). https:\/\/stacks.cdc.gov\/view\/cdc\/149213. Accessed 28 February 2025."},{"issue":"1","key":"13757_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12916-021-02204-0","volume":"20","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 2022;20(1):23. https:\/\/doi.org\/10.1186\/s12916-021-02204-0.","journal-title":"BMC Med"},{"issue":"1","key":"13757_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/QAD.0000000000002384","volume":"34","author":"A Chakraborty","year":"2020","unstructured":"Chakraborty A, Qato DM, Awadalla SS, Hershow RC, Dworkin MS. Antiretroviral therapy adherence among treatment-naive HIV-infected patients. AIDS. 2020;34(1):127\u201337. https:\/\/doi.org\/10.1097\/QAD.0000000000002384.","journal-title":"Aids"},{"key":"13757_CR18","unstructured":"US Centers for Disease Control and Prevention. Monitoring selected national hiv prevention and care objectives by using HIV surveillance data United States and 6 dependent areas, 2019. HIV surveillance supplemental report. Published online 2021. Accessed 1 August 2025. http:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance.html."},{"issue":"3","key":"13757_CR19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/QAI.0000000000002142","volume":"82","author":"KK Byrd","year":"2019","unstructured":"Byrd KK, Hou JG, Hazen R, et al. Antiretroviral adherence level necessary for HIV viral suppression using real-world data. J Acquir Immune Defic Syndr. 2019;82(3):245\u201351. https:\/\/doi.org\/10.1097\/QAI.0000000000002142.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"13757_CR20","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","volume":"5","author":"JM Molina","year":"2018","unstructured":"Molina JM, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e357\u201365. https:\/\/doi.org\/10.1016\/S2352-3018(18)30092-4.","journal-title":"Lancet HIV"},{"issue":"2","key":"13757_CR21","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","volume":"73","author":"PE Sax","year":"2021","unstructured":"Sax PE, Rockstroh JK, Luetkemeyer AF, et al. Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus. Clin Infect Dis. 2021;73(2):e485\u201393. https:\/\/doi.org\/10.1093\/cid\/ciaa988.","journal-title":"Clin Infect Dis"},{"issue":"10107","key":"13757_CR22","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","volume":"390","author":"J Gallant","year":"2017","unstructured":"Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(17)32299-7.","journal-title":"Lancet"},{"issue":"5","key":"13757_CR23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/INF.0000000000002577","volume":"39","author":"ME Levy","year":"2020","unstructured":"Levy ME, Griffith C, Ellenberger N, Monroe AK, Castel AD, Rakhmanina N. Outcomes of integrase inhibitor-based antiretroviral therapy in a clinical cohort of treatment-experienced children, adolescents, and young adults with HIV infection. Pediatr Infect Dis J. 2020;39(5):421\u201328. https:\/\/doi.org\/10.1097\/INF.0000000000002577.","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"13757_CR24","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S2352-4642(21)00165-6","volume":"5","author":"AH Gaur","year":"2021","unstructured":"Gaur AH, Cotton MF, Rodriguez CA, et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with hiv: week 48 results of a single-arm, open-label, multicentre, phase 2\/3 trial. Lancet Child Adolesc Health. 2021;5(9):642\u201351. https:\/\/doi.org\/10.1016\/S2352-4642(21)00165-6.","journal-title":"The Lancet Child Adolesc Health"},{"issue":"4","key":"13757_CR25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/QAI.0000000000002789","volume":"88","author":"C Orkin","year":"2021","unstructured":"Orkin C, Ajana F, Kityo C, et al. Brief report: efficacy and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in females living with hiv: an integrated analysis of 5 trials. J Acquir Immune Defic Syndr. 2021;88(4):393\u201398. https:\/\/doi.org\/10.1097\/QAI.0000000000002789.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"13757_CR26","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jadohealth.2014.11.009","volume":"56","author":"AL Agwu","year":"2015","unstructured":"Agwu AL, Lee L, Fleishman JA, et al. Aging and loss to follow-up among youth living with human immunodeficiency virus in the HIV research network. J Adolesc Health. 2015;56(3):345\u201351. https:\/\/doi.org\/10.1016\/j.jadohealth.2014.11.009.","journal-title":"J Adolesc Health"},{"issue":"3","key":"13757_CR27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/QAI.0b013e318258c696","volume":"60","author":"JA Fleishman","year":"2012","unstructured":"Fleishman JA, Yehia BR, Moore RD, Korthuis PT, Gebo KA. Establishment, retention, and loss to follow-up in outpatient hiv care. J Acquir Immune Defic Syndr. 2012;60(3):249\u201359. https:\/\/doi.org\/10.1097\/QAI.0b013e318258c696.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"13757_CR28","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/QAD.0b013e32834fa15e","volume":"26","author":"M Helleberg","year":"2012","unstructured":"Helleberg M, Engsig FN, Kronborg G, et al. Retention in a public healthcare system with free access to treatment: a Danish nationwide hiv cohort study. Aids. 2012;26(6):741\u201348. https:\/\/doi.org\/10.1097\/QAD.0b013e32834fa15e.","journal-title":"Aids"},{"key":"13757_CR29","unstructured":"Multicenter Aids Cohort Study (MACS) public data set | NIH: National Institute of Allergy and Infectious diseases. 2017 November 17. Accessed 10 September 2024. https:\/\/www.niaid.nih.gov\/research\/multicenter-aids-cohort-study-public-data-set."},{"key":"13757_CR30","unstructured":"University HealthSystems Consortium. CDP online report. 2008. https:\/\/www.uhc.edu. Accessed 10 September 2024."},{"key":"13757_CR31","unstructured":"U.S. Bureau of Labor Statistics. Consumer price index: medical care. https:\/\/data.bls.gov\/cgi-bin\/surveymost. Accessed 10 September 2024."},{"key":"13757_CR32","unstructured":"Centers for Medicare and Medicaid Services. Medicare Physician fee schedule 2023. https:\/\/www.cms.gov\/medicare\/payment\/fee-schedules\/physician. Accessed 10 September 2024."},{"key":"13757_CR33","unstructured":"Clinical Laboratory Fee Schedule. Baltimore, MD: Centers for Medicare and Medicaid Services. https:\/\/www.cms.gov\/medicare\/payment\/fee-schedules\/clinical-laboratory-fee-schedule-clfs. Accessed 10 September 2023."},{"issue":"2","key":"13757_CR34","doi-asserted-by":"publisher","first-page":"E240","DOI":"10.9778\/cmajo.20150087","volume":"4","author":"R Ng","year":"2016","unstructured":"Ng R, Kendall CE, Burchell AN, et al. Emergency department use by people with hiv in Ontario: a population-based cohort study. CMAJ Open. 2016;4(2):E240\u201348. https:\/\/doi.org\/10.9778\/cmajo.20150087.","journal-title":"CMAJ Open"},{"issue":"6","key":"13757_CR35","first-page":"5","volume":"15","author":"KA Gebo","year":"2003","unstructured":"Gebo KA, Moore RD, Fleishman JA. The hiv research network: a unique opportunity for real time clinical utilization analysis in hiv. Hopkins HIV Rep. 2003;15(6):5\u20136.","journal-title":"Hopkins HIV Rep"},{"key":"13757_CR36","unstructured":"Dawson L, Kates J, Roberts T, Published PC. Medicaid and people with hiv. KFF. 2023 March 27. https:\/\/www.kff.org\/hivaids\/issue-brief\/medicaid-and-people-with-hiv\/. Accessed 12 February 2025."},{"key":"13757_CR37","unstructured":"Medicaid hospital payment: a comparison across states and to Medicare. MACPAC. 2017 April 5. https:\/\/www.macpac.gov\/publication\/medicaid-hospital-payment-a-comparison-across-states-and-to-medicare\/. Accessed 12 February 2025."},{"key":"13757_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/1471-2334-14-217","volume":"14","author":"TL Johnson","year":"2014","unstructured":"Johnson TL, Toliver JC, Mao L, Oramasionwu CU. Differences in outpatient care and treatment utilization for patients with HIV\/HCV coinfection, hiv, and HCV monoinfection, a cross-sectional study. BMC Infect Dis. 2014;14:217. https:\/\/doi.org\/10.1186\/1471-2334-14-217.","journal-title":"BMC Infect Dis"},{"key":"13757_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ajem.2021.12.025","volume":"53","author":"KA Siddiqi","year":"2022","unstructured":"Siddiqi KA, Liu Y, Ding DD, Olatosi BA. Estimating resource utilization for emergency department visits by patients\u2019 hiv seropositivity in the United States, 2009 to 2018. Am J Emerg Med. 2022;53:73\u201379. https:\/\/doi.org\/10.1016\/j.ajem.2021.12.025.","journal-title":"Am J Emerg Med"},{"key":"13757_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ajem.2022.05.035","volume":"58","author":"G Pickens","year":"2022","unstructured":"Pickens G, Smith MW, Kw M, Mummert A, Karaca Z. Trends in treatment costs of U.S. emergency department visits. Am J Emerg Med. 2022;58:89\u201394. https:\/\/doi.org\/10.1016\/j.ajem.2022.05.035.","journal-title":"Am J Emerg Med"},{"issue":"4","key":"13757_CR41","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1001\/jamainternmed.2019.7108","volume":"180","author":"NC McCann","year":"2020","unstructured":"McCann NC, Horn TH, Hyle EP, Walensky RP. Hiv antiretroviral therapy costs in the United States, 2012-2018. JAMA Intern Med. 2020;180(4):601\u201303. https:\/\/doi.org\/10.1001\/jamainternmed.2019.7108.","journal-title":"JAMA Intern Med"},{"key":"13757_CR42","unstructured":"Office of Procurement. Acquisition, and logistics (opal). Federal supply schedule. us department of veterans affairs. https:\/\/www.va.gov\/opal\/nac\/fss\/pharmprices.asp. Accessed 10 September 2024."},{"key":"13757_CR43","doi-asserted-by":"publisher","first-page":"004695802096938","DOI":"10.1177\/0046958020969381","volume":"57","author":"AA Leibowitz","year":"2020","unstructured":"Leibowitz AA, Tan D, Gildner JL. The effect of hospice on end-of-life costs for terminal Medicare patients with hiv. Inquiry. 2020;57:0046958020969381. https:\/\/doi.org\/10.1177\/0046958020969381.","journal-title":"Inquiry"},{"issue":"6","key":"13757_CR44","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1111\/1475-6773.01113","volume":"37","author":"DR Hoover","year":"2002","unstructured":"Hoover DR, Crystal S, Kumar R, Sambamoorthi U, Cantor JC. Medical expenditures during the last year of life: findings from the 1992\u20131996 Medicare current beneficiary survey. Health Serv Res. 2002;37(6):1625\u201342. https:\/\/doi.org\/10.1111\/1475-6773.01113.","journal-title":"Health Serv Res"},{"key":"13757_CR45","unstructured":"World Health Organization. Interim who clinical staging of HIV\/AIDS and HIV\/AIDS case definitions for surveillance. 2005. https:\/\/iris.who.int\/bitstream\/handle\/10665\/69058\/WHO_HIV_2005.02.pdf. Accessed 10 September 2024."},{"key":"13757_CR46","unstructured":"Homepage of Mark Cuban Cost Plus Drugs. Accessed 10 September 2024. https:\/\/costplusdrugs.com\/."},{"key":"13757_CR47","unstructured":"66th Office of AIDS Research Advisory Committee Meeting.. 2024. https:\/\/videocast.nih.gov\/watch=54677. Accessed 26 June 2024."},{"key":"13757_CR48","unstructured":"Overview: Recommendations for Antiretroviral Drugs Use During Pregnancy | NIH. 2024 January 31. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/perinatal\/recommendations-arv-drugs-pregnancy-overview. Accessed 10 September 2024."},{"issue":"6","key":"13757_CR49","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s10461-013-0687-6","volume":"18","author":"JC Kerr","year":"2014","unstructured":"Kerr JC, Valois RF, Diclemente RJ, et al. HIV-related stigma among African-American youth in the northeast and southeast US. AIDS Behav. 2014;18(6):1063\u201367. https:\/\/doi.org\/10.1007\/s10461-013-0687-6.","journal-title":"AIDS Behav"},{"issue":"11","key":"13757_CR50","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1056\/NEJM200103153441108","volume":"344","author":"KA Freedberg","year":"2001","unstructured":"Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for hiv disease. N Engl J Med. 2001;344(11):824\u201331. https:\/\/doi.org\/10.1056\/NEJM200103153441108.","journal-title":"N Engl J Med"},{"issue":"4","key":"13757_CR51","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMp1710914","volume":"378","author":"EG Martin","year":"2018","unstructured":"Martin EG, Schackman BR. Treating and preventing hiv with generic drugs \u2014 barriers in the United States. NEJM Evid. 2018;378(4):316\u201319. https:\/\/doi.org\/10.1056\/NEJMp1710914.","journal-title":"NEJM Evid"},{"key":"13757_CR52","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with hiv. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new. Accessed 23 July 2025."},{"key":"13757_CR53","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12981-022-00477-w","volume":"19","author":"C Kilcrease","year":"2022","unstructured":"Kilcrease C, Yusuf H, Park J, et al. Realizing the promise of long-acting antiretroviral treatment strategies for individuals with hiv and adherence challenges: an illustrative case series. AIDS Res Ther. 2022;19:56. https:\/\/doi.org\/10.1186\/s12981-022-00477-w.","journal-title":"AIDS Res Ther"},{"key":"13757_CR54","unstructured":"What\u2019s new: adult and adolescent arv hiv clinical guidelines | nih. 2024 February 27. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new. Accessed 10 September 2024."},{"key":"13757_CR55","unstructured":"340B drug pricing program |. HRSA. https:\/\/www.hrsa.gov\/opa. Accessed 10 September 2024."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13757-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-13757-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13757-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:03:39Z","timestamp":1768341819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-025-13757-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13757"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-13757-8","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Allison Agwu serves on a Gilead scientific advisory board, as a site investigator under clinical research contract managed through JHU, and on a ViiV scientific advisory board. Dr. Maria Trent is involved in other research and training from The National Institutes of Health and has received research supplies from Speedx, Ltd (Australia) through a material transfer agreement with JHU for unrelated federally funded research. Other authors have no disclosures or conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}